Business
Long Term Incentive Plan Award
EKF Diagnostics Holdings plc announced that its Chief Financial Officer, Helen Jones, has been awarded 282,353 ordinary shares under the company's Long Term Incentive Plan, with vesting contingent on Adjusted EBITDA per share growth over a three-year period, requiring at least 25% growth for full vesting and 10% growth for 25% vesting. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n\n\n \nEKF Diagnostics Holdings plc\n(\"EKF\" or the \"Company\")\n \nLong Term Incentive Plan Award\n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that the Board, following the recommendation of the remuneration committee and after consulting its advisers, has today made the following award (the \"Award\") to Helen Jones (Chief Financial Officer) under the Company's established LTIP that was adopted on 9 September 2025:\n \n\n\n\n\nIndividual\n\n\nPosition\n\n\nType of Award\n\n\nNumber of ordinary shares subject to LTIP award\n\n\n\n\nHelen Jones\n\n\nChief Financial Officer\n\n\nLTIP award - nominal cost option\n\n\n282,353\n\n\n\n\n \nThe Award has a performance period from the grant date to the third anniversary of the grant date and are subject to the following performance criteria.\n \nThe Award shall vest on a sliding scale depending on the total percentage growth of Adjusted EBITDA per share over the Performance Period, as follows:\n \n\n\n\n\n(i) \n\n\nGrowth of 25% or higher: 100% of the Award vests.\n\n\n\n\n(ii)\n\n\nBetween 10% and 25% growth: Vesting shall occur on a straight-line basis between 25% and 100%.\n\n\n\n\n(iii)\n\n\n10% growth: 25% of the Award vests; or\n\n\n\n\n(iv)\n\n\nBelow 10% growth: 0% of the Award vests.\n\n\n\n\n \nJenny Winter, Chair of the Remuneration committee, commented:\n\"It is important that our newly appointed CFO, Helen, is rewarded such that her performance indicators align with shareholder value creation. I am satisfied that these incentivisation arrangements achieve that objective.\"\n \n\n\n\n\nEKF Diagnostics Holdings plc\n\n\nwww.ekfdiagnostics.com\n\n\n\n\nJulian Baines, Executive Chair\n\n\n Via Walbrook PR\n\n\n\n\nGavin Jones, Chief Executive Officer\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 (0)20 7496 3000\n\n\n\n\nPhil Davies / Patrick Weaver\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \n\n \nAbout EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)\n \nEKF is an...